Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study).
Tobias J LangePilar Escribano-SubiasAudrey MullerCatarina C FernandesMartina FontanaTatiana RemenovaStefan SöderbergSean GainePublished in: Advances in therapy (2024)
In clinical settings, selexipag is initiated across all risk groups, predominantly as triple therapy. Only 45% of patients being at low/intermediate-low risk at selexipag initiation suggests an opportunity for more frequent patient monitoring and earlier treatment escalation, given that 4-strata risk assessment was prognostic for hospitalisations and survival in this contemporary PAH cohort. A graphical abstract is available with this article.
Keyphrases
- pulmonary arterial hypertension
- risk assessment
- pulmonary artery
- pulmonary hypertension
- end stage renal disease
- newly diagnosed
- human health
- heavy metals
- ejection fraction
- chronic kidney disease
- prognostic factors
- stem cells
- clinical trial
- case report
- patient reported outcomes
- mesenchymal stem cells
- coronary artery
- african american